Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ib/II open-label study of 莱古比星 injection plus nivolumab in advanced or metastatic non-small cell lung cancer
CTR20250876Phase 2Active
- Sponsor
- Shanghai Qinheli Biotechnology
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Qinheli Biotechnology. Started Mar 2025; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20250876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250876.